U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H5O7.3Ag
Molecular Weight 512.7044
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SILVER CITRATE

SMILES

C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Ag+].[Ag+].[Ag+]

InChI

InChIKey=QUTYHQJYVDNJJA-UHFFFAOYSA-K
InChI=1S/C6H8O7.3Ag/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3

HIDE SMILES / InChI

Molecular Formula Ag
Molecular Weight 107.8682
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H5O7
Molecular Weight 189.1
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: http://health.mo.gov/living/families/oralhealth/pdf/silver-diamine-fluoride.pdf | https://www.ncbi.nlm.nih.gov/pubmed/21118796 | https://www.ncbi.nlm.nih.gov/pubmed/24373856 | https://www.ncbi.nlm.nih.gov/pubmed/19641152

Silver Diamine Fluoride is a clinically applied treatment that controls active dental caries and aids in preventing further progression of the disease. Silver Diamine Fluoride has a dual mechanism of action resulting from the combination of its ingredients. The silver component acts as an anti-microbial agent killing bacteria and preventing the formation of new biofilm, while the fluoride acts to prevent further demineralization of tooth structure. Silver diamine fluoride is a safe, effective treatment for dental caries across the age spectrum. Application twice-per-year outperforms all minimally invasive options including the atraumatic restorative technique – with which it is compatible but 20 times less expensive. It approaches the success of dental fillings after 2 or more years, and again, prevents future caries – while fillings do not. Silver diamine fluoride is more effective as a primary preventative than any other available material, with the exception of dental sealants which are >10 times more expensive and need to be monitored.

Originator

Sources: Vestsi Akademii Navuk BSSR, Seryya Khimichnykh Navuk, Issue 2, Pages 69-73, Journal, 1990https://www.ncbi.nlm.nih.gov/pubmed/20429870
Curator's Comment:: The medical uses of silver date back to at least the time of Hippocrates

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Palliative

Approved Use

Antiseptic Wound Cauterization
Primary
Advantage Arrest Silver Diamine Fluoride
Primary
Primary
Advantage Arrest Silver Diamine Fluoride
Curative
Primary
Colloidal silver iodide

Approved Use

Solution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose.
Primary
Colloidal silver iodide

Approved Use

Solution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose.
Primary

Approved Use

Prophylaxis of gonococcal ophthalmia neonatorum. AAP recommends use of topical silver nitrate, povidone-iodine, or possibly erythromycin for prophylaxis of nongonococcal nonchlamydial conjunctivitis in neonates, ideally administered shortly after birth.
PubMed

PubMed

TitleDatePubMed
Lack of genotoxicity of silver iodide in the SCE assay in vitro, in vivo, and in the Ames/microsome test.
1998
A chemically intelligent antimicrobial coating for urologic devices.
2000 Feb
New disinfection and sterilization methods.
2001 Mar-Apr
Comparative efficacy of hand hygiene agents in the reduction of bacteria and viruses.
2005 Mar
Photocatalytic degradation of pathogenic bacteria with AgI/TiO2 under visible light irradiation.
2007 Apr 24
Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli.
2008 Apr
Topical antimicrobials for burn wound infections.
2010 Jun
Development of silica-coated silver iodide nanoparticles and their biodistribution.
2012 Dec
Cleaning and decontamination efficacy of wiping cloths and silver dihydrogen citrate on food contact surfaces.
2012 Jul
A novel silver iodide metalo-drug: experimental and computational modelling assessment of its interaction with intracellular DNA, lipoxygenase and glutathione.
2014 Apr 22
An alternate technique of care using silver fluoride followed by stannous fluoride in the management of root caries in aged care.
2016 Mar-Apr
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Toxicity data
Lesions, without an accompanying pulp exposure were treated with a solution of 40% silver fluoride for 60 seconds. This was immediately followed by the application of a 10% stannous fluoride paste. A piece of dissolving adhesive wafer was adapted over each treatment site and then allowed to dissolve in the oral fluids. Clinical examination showed that all treated lesions had an uninterrupted black surface 24 hours after treatment.
Route of Administration: Topical
Substance Class Chemical
Created
by admin
on Sat Jun 26 04:37:38 UTC 2021
Edited
by admin
on Sat Jun 26 04:37:38 UTC 2021
Record UNII
CKA421A1J7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SILVER CITRATE
INCI   MI   WHO-DD  
INCI  
Official Name English
SILVER CITRATE [WHO-DD]
Common Name English
SILVER CITRATE [INCI]
Common Name English
2-HYDROXY-1,2,3-PROPANETRICARBOXYLIC ACID SILVER SALT
Common Name English
1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-, SILVER(1+) SALT (1:3)
Common Name English
TRISILVER CITRATE
Systematic Name English
SILVER CITRATE [MI]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 310.548
Created by admin on Sat Jun 26 04:37:39 UTC 2021 , Edited by admin on Sat Jun 26 04:37:39 UTC 2021
Code System Code Type Description
ECHA (EC/EINECS)
204-786-8
Created by admin on Sat Jun 26 04:37:39 UTC 2021 , Edited by admin on Sat Jun 26 04:37:39 UTC 2021
PRIMARY
RXCUI
1306066
Created by admin on Sat Jun 26 04:37:39 UTC 2021 , Edited by admin on Sat Jun 26 04:37:39 UTC 2021
PRIMARY RxNorm
PUBCHEM
101599
Created by admin on Sat Jun 26 04:37:39 UTC 2021 , Edited by admin on Sat Jun 26 04:37:39 UTC 2021
PRIMARY
FDA UNII
CKA421A1J7
Created by admin on Sat Jun 26 04:37:39 UTC 2021 , Edited by admin on Sat Jun 26 04:37:39 UTC 2021
PRIMARY
CAS
126-45-4
Created by admin on Sat Jun 26 04:37:39 UTC 2021 , Edited by admin on Sat Jun 26 04:37:39 UTC 2021
PRIMARY
DRUG BANK
DB11233
Created by admin on Sat Jun 26 04:37:39 UTC 2021 , Edited by admin on Sat Jun 26 04:37:39 UTC 2021
PRIMARY
MERCK INDEX
M9920
Created by admin on Sat Jun 26 04:37:39 UTC 2021 , Edited by admin on Sat Jun 26 04:37:39 UTC 2021
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY